14.83

11.67% 1.55

After Hours: 15.20 0.37 +2.49%

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $14.83, with a volume of 3.15M. It is up +11.67% in the last 24 hours and up +143.91% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Previous Close:

$13.28

Open:

$13.54

24h Volume:

3.15M

Relative Volume:

1.94

Market Cap:

$766.68M

Revenue:

$170.44M

Net Income/Loss:

$-193.88M

P/E Ratio:

-3.9503

EPS:

-3.7541

Net Cash Flow:

$-126.38M

1W Performance:

+25.36%

1M Performance:

+143.91%

6M Performance:

+4.58%

1Y Performance:

+69.68%

1-Day Range:

$13.53

$15.30

1-Week Range:

$11.63

$15.30

52-Week Range:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

371

Twitter

@REGENXBIO

Next Earnings Date

2026-08-06

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	14.83	619.34M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Feb-11-25	Downgrade	Goldman	Buy → Neutral
Feb-07-25	Resumed	Raymond James	Outperform
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

Jul 01, 2026

RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Jul 01, 2026

Regenxbio CMO Steve Pakola sells $688,755 in company stock. By Investing.com - Investing.com Canada

Jul 01, 2026

Regenxbio Chief Medical Officer Sold Shares Worth Over $688K - TradingView

Jul 01, 2026

Proposed 43,206-share sale for RGNX (NASDAQ: RGNX) tied to option exercise - Stock Titan

Jul 01, 2026

REGENXBIO (RGNX) amends Schedule TO to update employee option exchange content - Stock Titan

Jul 01, 2026

H.C. Wainwright reiterates Regenxbio stock rating on trial milestone - Investing.com

Jul 01, 2026

H.C. Wainwright reiterates Regenxbio stock rating on trial milestone By Investing.com - Investing.com Nigeria

Jul 01, 2026

Jun 29, 2026

REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 29, 2026

REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

REGENXBIO doses first patient in DR trial - grafa.com

Jun 29, 2026

Regenxbio doses first patient in diabetic retinopathy trial - Investing.com

Jun 29, 2026

Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial - TipRanks

Jun 29, 2026

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - The AI Journal

Jun 29, 2026

REGENXBIO doses first patient in Phase IIb/III trial for diabetic retinopathy therapy - Traders Union

Jun 29, 2026

$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan

Jun 29, 2026

REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Regenxbio shares rise on plans to resubmit Navsunli BLA for MPS II - MSN

Jun 28, 2026

Liquidity Mapping Around (RGNX) Price Events - Stock Traders Daily

Jun 28, 2026

Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing - Seeking Alpha

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView

Jun 27, 2026

Enterprise value to revenue forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView

Jun 27, 2026

Enterprise value to revenue forward of REGENXBIO, Inc. – MUN:RB0 - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of REGENXBIO, Inc. – MUN:RB0 - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of REGENXBIO, Inc. – MUN:RB0 - TradingView

Jun 27, 2026

Price to sales forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView

Jun 27, 2026

Price to book forward of REGENXBIO, Inc. – MUN:RB0 - TradingView

Jun 27, 2026

Price to earnings forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView

Jun 27, 2026

Jun 26, 2026

REGENXBIO, Inc. Actuals & Estimates (NASDAQ:RGNX) - TradingView

Jun 26, 2026

REGENXBIO, Inc. Actuals & Estimates (DUS:RB0) - TradingView

Jun 26, 2026

Phase III wins in May span gene therapy, gout, and pancreatic cancer - BioWorld News

Jun 26, 2026

What's Going On With Capricor Therapeutics Stock On Friday? - Sahm

Jun 26, 2026

Jun 25, 2026

REGENXBIO, Inc. Actuals & Estimates (LS:A140E0) - TradingView

Jun 25, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Jun 25, 2026

RGNX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

FDA Clears Path for NAVSUNLI BLA Resubmission in MPS II, No Additional Studies Required - NeurologyLive

Jun 25, 2026

H.C. Wainwright reiterates Regenxbio stock rating on trial completion - Investing.com UK

Jun 25, 2026

H.C. Wainwright reiterates Regenxbio stock rating on trial completion By Investing.com - Investing.com South Africa

Jun 25, 2026

Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Jun 25, 2026

Regenxbio completes dosing in Duchenne gene therapy study - The Pharmaletter

Jun 25, 2026

Jun 24, 2026